Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Colorectal Neoplasms 146Head and Neck Neoplasms 80Squamous Cell Carcinoma of Head and Neck 69Rectal Neoplasms 46Colonic Neoplasms 42Carcinoma, Non-Small-Cell Lung 39Neoplasm Metastasis 35Neoplasms 25Carcinoma, Squamous Cell 20Pancreatic Neoplasms 17Lung Neoplasms 16Esophageal Neoplasms 15Stomach Neoplasms 12Recurrence 11Laryngeal Neoplasms 11Mouth Neoplasms 10Oropharyngeal Neoplasms 8Esophageal Squamous Cell Carcinoma 8Breast Neoplasms 8Adenocarcinoma Of Esophagus 8Tongue Neoplasms 7Uterine Cervical Neoplasms 6Nasopharyngeal Carcinoma 6Laryngeal Diseases 6Hypopharyngeal Neoplasms 6Colorectal Cancer Metastatic 6Carcinoma 6Adenocarcinoma of Lung 6Salivary Gland Neoplasms 5Cholangiocarcinoma 4

Interventions

Leucovorin 2Irinotecan 2Fluorouracil 2dostarlimab 1avelumab 1Varenicline 1Tobacco Use Cessation Devices 1Temozolomide 1Radiotherapy 1Panitumumab 1Nicotine Chewing Gum 1Cetuximab 1Bupropion 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms, Second Primary × Cetuximab × Clear all
NCT05217069 2025-04-16

FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC

Ludwig-Maximilians - University of Munich

Phase 2 Completed
57 enrolled
Tumor-Agnostic

Neoplasms, Second Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡